2021
How we treat HER2-positive brain metastases
Stavrou E, Winer EP, Lin NU. How we treat HER2-positive brain metastases. ESMO Open 2021, 6: 100256. PMID: 34482180, PMCID: PMC8424223, DOI: 10.1016/j.esmoop.2021.100256.Peer-Reviewed Original ResearchConceptsHER2-positive brain metastasesHuman epidermal growth factor 2Brain metastasesAdvanced diseaseBreast cancerCentral nervous system metastasesHER2-positive breast cancerEpidermal growth factor 2Nervous system metastasesExperienced multidisciplinary teamSurvival of patientsCentral nervous system activitySite of diseaseNervous system activityUnique clinical challengesAssociated morbiditySystemic therapyGrowth factor 2Clinical challengeReview of agentsClinical scenariosMultidisciplinary teamMetastasisSystem activityDisease
2020
Expanding criteria for prognostic stage IA disease in HR+ breast cancer.
Kantor O, King T, Shak S, Russell C, Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Clinical Oncology 2020, 38: 550-550. DOI: 10.1200/jco.2020.38.15_suppl.550.Peer-Reviewed Original ResearchStage IA diseaseRecurrence scoreIA diseaseN categoryOncotype DX recurrence scoreNode-positive diseaseAJCC staging systemDX recurrence scoreRS resultsRS 11Median followDSS ratesPositive diseaseSEER databaseReceptor statusStaging systemEvidence of utilityScore 11Breast cancerTrial dataDiseaseAdditional studiesPatientsStagingDSS
2018
69 Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer
Waks A, Winer E. 69 Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. 2018, 885-906.e8. DOI: 10.1016/b978-0-323-35955-9.00069-6.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerHER2-positive metastatic breast cancerTriple-negative breast cancerTriple-negative diseaseBRCA-deficient breast cancersUnderstanding of treatmentDistinct disease subtypesBrain metastasesOverall survivalSystemic therapyClinical efficacyNovel therapiesDisease subtypesTherapyCancerHER2ChemotherapyImportant advancesImmunotherapyPertuzumabPatientsMetastasisSubtypesDisease
2017
T-DM1 — an important agent in the history of breast cancer management
Metzger-Filho O, Winer EP. T-DM1 — an important agent in the history of breast cancer management. Nature Reviews Clinical Oncology 2017, 14: 651-652. PMID: 28786416, DOI: 10.1038/nrclinonc.2017.123.Peer-Reviewed Original ResearchConceptsT-DM1HER2-positive breast cancerOverall survival benefitFavorable safety profileBreast cancer managementRelevant therapeutic targetTH3RESA trialProlonged followSurvival benefitSafety profileBreast cancerCancer managementTherapeutic targetLater linesImportant agentsPatientsHER2FollowCancerDiseaseTrialsABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.
Chen W, Winer E, Barry W, Hudis C, Openshaw T, Visvanathan K, Symington B, Matyka C, Holmes M. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal Of Clinical Oncology 2017, 35: tps586-tps586. DOI: 10.1200/jco.2017.35.15_suppl.tps586.Peer-Reviewed Original ResearchAspirin usersRegular aspirin usersBreast cancer survivalMultiple epidemiologic studiesAnti-tumor activityMetastatic adenocarcinomaRandomized trialsDecreased riskCancer survivalCardiovascular diseaseMetastatic cancerEpidemiologic studiesAvailable drugsVivo evidenceAspirinMultiple pathwaysAdenocarcinomaCancerDiseaseTrials
2016
I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment
Carey LA, Winer EP. I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment. New England Journal Of Medicine 2016, 375: 83-84. PMID: 27406352, DOI: 10.1056/nejme1603691.Peer-Reviewed Original Research
2012
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Annals Of Oncology 2012, 24: 283-291. PMID: 23022997, PMCID: PMC3551479, DOI: 10.1093/annonc/mds286.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerHER2-positive diseaseEstrogen receptor statusBreast cancerReceptor statusClinical outcomesEpidermal growth factor receptor 2 overexpressionHuman epidermal growth factor receptor 2 (HER2) overexpressionDistinct subtypesFuture clinical trialsEfficacy of therapyMetastatic settingNeoadjuvant therapyMetastatic diseaseER statusSurvival outcomesClinical trialsPatterns of disseminationTherapyCancerDiseaseSubstantial minorityOutcomesSubtypesHeterogeneous entityA dickens tale of the treatment of advanced breast cancer: the past, the present, and the future.
Sledge GW, Cardoso F, Winer EP, Piccart MJ. A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. American Society Of Clinical Oncology Educational Book 2012, 28-38. PMID: 24451704, DOI: 10.14694/edbook_am.2012.32.306.Peer-Reviewed Original ResearchThe Effect of Age on Delay in Diagnosis and Stage of Breast Cancer
Partridge AH, Hughes ME, Ottesen RA, Wong Y, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. The Oncologist 2012, 17: 775-782. PMID: 22554997, PMCID: PMC3380876, DOI: 10.1634/theoncologist.2011-0469.Peer-Reviewed Original ResearchConceptsHigher stage diseaseBreast cancerYoung womenStage diseaseNational Comprehensive Cancer Network centersInitial signsYounger ageHigher stageBreast cancer diagnosisAdvanced diseaseEffect of ageIndependent predictorsSymptomatic diseaseStage ICancerDiagnosisDiseaseSymptomsCancer diagnosisWomenOlder counterpartsAgeSimilar adjustmentSignsDays1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, Saghir N, Ganz P, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). The Breast 2012, 21: 242-252. PMID: 22425534, DOI: 10.1016/j.breast.2012.03.003.Peer-Reviewed Original Research
2011
Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates?
Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? The Breast Journal 2011, 18: 23-27. PMID: 22017599, DOI: 10.1111/j.1524-4741.2011.01178.x.Peer-Reviewed Original ResearchConceptsPositive sentinel lymph nodesSentinel lymph node biopsySentinel lymph nodesAxillary node dissectionCompletion axillary node dissectionLow-risk patient populationAdjuvant treatment patternMedian patient agePercent of patientsLymph node biopsyStandard of careNodal radiationNode dissectionMicrometastatic diseaseNode biopsyLymph nodesPatient ageTreatment patternsPatient populationBreast cancerClinical dataRadiation therapyPatientsDiseaseMacrometastasisShould a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer?
Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer? International Journal Of Breast Cancer 2011, 2011: 973245. PMID: 22295240, PMCID: PMC3262582, DOI: 10.4061/2011/973245.Peer-Reviewed Original ResearchAxillary diseaseSLN biopsyHigh riskNegative SLN biopsy resultsHigh-risk breast cancerNegative SLN biopsySLN biopsy resultsLymph node irradiationSentinel node biopsyBreast cancer patientsAxillary irradiationNode irradiationClinical characteristicsNodal biopsyNodal involvementNode biopsyAdditional surgeryBiopsy resultsCancer patientsBreast cancerBiopsyPatientsBayesian nomogramTest characteristicsDisease
2007
Sarcoidosis Mimicking Metastatic Breast Cancer
Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP. Sarcoidosis Mimicking Metastatic Breast Cancer. Clinical Breast Cancer 2007, 7: 804-810. PMID: 18021484, DOI: 10.3816/cbc.2007.n.044.Peer-Reviewed Original ResearchInvasive breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network 2007, 5: 246-312. PMID: 17439758, DOI: 10.6004/jnccn.2007.0025.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerBreast cancer mortalityAmerican Cancer SocietyMore effective treatmentsCommon malignancyCancer mortalityCancer deathLung cancerCancer SocietyEffective treatmentNew casesCancerEarly detectionUnited StatesTreatmentGuidelinesMalignancyMortalityIncidenceDiseaseDiagnosisWomen
2006
Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future
Hudis CA, Winer EP. Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future. Clinical Cancer Research 2006, 12: 3576s-3580s. PMID: 16740788, DOI: 10.1158/1078-0432.ccr-06-9016.Peer-Reviewed Original Research
2005
Breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network 2005, 3: 238-89. PMID: 16002000, DOI: 10.6004/jnccn.2005.0015.Peer-Reviewed Original Research
2004
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Journal Of Clinical Oncology 2004, 22: 628-628. DOI: 10.1200/jco.2004.22.14_suppl.628.Peer-Reviewed Original ResearchA comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Journal Of Clinical Oncology 2004, 22: 628-628. DOI: 10.1200/jco.2004.22.90140.628.Peer-Reviewed Original Research
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/jco.1999.17.8.2506.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerTreatment failureDisease progressionPain controlSurvival durationProstate cancerResults of treatmentOverall survivalPalliative optionMore frequent responsesPatientsHydrocortisoneLife parametersNew drugsCancerMitoxantroneProgressionSurvivalDiseasePossible benefitsMenTreatmentFrequent responseFailureDuration
1997
A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification
Warmuth M, Sutton L, Winer E. A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification. The American Journal Of Medicine 1997, 102: 407-415. PMID: 9217624, DOI: 10.1016/s0002-9343(97)00093-4.Peer-Reviewed Original ResearchConceptsRisk factor modificationBreast cancerFactor modificationGenetic testingBreast cancer riskBreast cancer casesHereditary breast cancerPotential prophylactic measuresClinical managementBRCA2 mutationsCancer casesCancer riskProphylactic measuresWay patientsCancerGene mutationsGenetic mutationsGenetic testsGenetic aspectsMajor advancesBRCA1MutationsScreeningPatientsDisease